Metfogamma

Metformin Hydrochloride, the active ingredient in Metfogamma, is a biguanide presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, thereby helping lower blood‑sugar levels.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Metfogamma (metformin hydrochloride) is indicated for conditions related to impaired glucose metabolism, primarily type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes: lowers fasting glucose and helps prevent progression to diabetes. - Polycystic ovary syndrome (PCOS): assists in restoring ovulatory cycles and reducing insulin resistance.

Metfogamma may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient gastrointestinal discomfort. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: elevated liver enzymes. - Pancreatitis: inflammation of the pancreas. - Skin reactions: rash or Stevens‑Johnson syndrome. - Renal impairment: worsening kidney function in susceptible patients.

Metfogamma requires careful monitoring and patient education to minimise risks.

- Renal function assessment: evaluate creatinine clearance before initiation and periodically. - Hepatic function monitoring: check liver enzymes in patients with liver disease. - Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia or severe infection. - Concomitant medication review: assess for drugs that may increase metformin levels. - Dose adjustment in elderly: consider lower starting dose and slower titration. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metfogamma can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Alcohol: potentiates risk of lactic acidosis. - Coadministration with insulin or sulfonylureas: can cause severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metformin plasma concentrations. - Loop diuretics (e.g., furosemide): can affect renal clearance. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Oral contraceptives: may slightly increase metformin levels.